Strategies for developing a Helicobacter pylori vaccine

Current Opinion in Gastroenterology

Volumn 15, Issue 6, 1999, Pages 557-561

  Banerjee, Subhas ^a   Michetti, Pierre ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; CD4 ANTIGEN; HELICOBACTER PYLORI VACCINE; POLYGLACTIN; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL TRIAL; DRUG SAFETY; HELICOBACTER PYLORI; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NONHUMAN; ORAL DRUG ADMINISTRATION; SPECIES DIFFERENCE; STOMACH PROTECTION; VACCINATION;

EID: 0032734860     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199911000-00017     Document Type: Article

References (45)

1. Pisani P, Parkin DM, Munoz N, Ferlay J: Cancer and infection: estimates of the attributable fraction in 1900. Cancer Epidemiol Biomarkers Prev 1997, 6:389-400.
2. Sullivan PB, Thomas JE, Wight DG, Neale G, Eastham EJ, Corrah T, et al.: Helicobacter pylori in Gambian children with chronic diarrhea and malnutrition. Arch Dis Child 1990, 65:189-191.
3. Ramirez-Ramos A, Gilman RH, Leon-Barua R, Recavarren-Arce S, Watanabe J, Salazar G, et al.: Rapid recurrence of Helicobacter pylori infection in Peruvian patients after successful eradication. Clin Infect Dis 1997, 25:1027-1031.
4. Coleman MP, Esteve J, Damiecki P, Arslan A, Renard H: Trends in cancer incidence and mortality. IARC Sci Publ 1993, 121:193-224.
5. Tsugawa M, Shachter R, Owens DK, Personnel J: Cost-effectiveness of vaccine development for H. pylori using the Institute of Medicine model. Gastroenterology 1998, 114:A313.
6. Czinn SJ, Cai A, Nedrud JG: Protection of germ free mice from infection by Helicobacter felis after active oral or passive lgA immunization. Vaccine 1993, 11:637-642.
7. Chen M, Lee A, Hazeff S, Hu P, Li Y: Immunization against gastric infection with helicobacter species: first step in the prophylaxis of gastric cancer? Zentralbl Bakteriol 1993, 280;155-165.
8. Doidge C, Gust I, Lee A, Buck F, Hazell S, Manne U: Therapeutic immunization against helicobacter infection. Lancet 1994, 343:913-914.
9. Corthésy-Theulaz I, Porto N, Glauser M, Saraga E, Vaney AC, Haas R, et al.: Oral immunization with Helicobacter pylori urease B subunit as a treatment against helicobacter infection in mice. Gastroenterology 1995. 109:115-121.
10. Cuenca R, Blancha TG, Czinn SJ, Nedrud JG, Monath TP, Lee CK, Redline RW: Therapeutic immunization against Helicobacter mustelae in naturally infected ferrets. Gastroenterology 1996, 110:1770-1775.
11. Birkholz S, Schneider T, Knipp U, Stallmach A, Zeitz M: Decreased Helicobacter pylori-specific gastric secretory lgA antibodies in infected patients. Digestion 1998, 59:638-645.
12. Weltzin R, Kleanthous H, Guirakhoo F, Monath TP, Lee CK: Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection. Vaccine 1997, 15:370-376.
13. Ermak TH, Giannasca PJ, Nichols R, Myers GA, Nedrud J, Weltzin RA, et al.: Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J Exp Med 1998, 188:1-12. This elegant and extensive study defines T- and B-cell elements required for protection of the gastric mucosa against Helicobacter species infection. The authors show that MHC II, but not MHC I or B-cell response, is required for protection.
14. Fan XJ, Chua A, Shahi CN, McDevitt J, Keeling PW, Kelleher D: Gastric T lymphocyte responses to Helicobacter pylori in patients with H. pylori colonization. Gut 1994, 35:1379-1384.
15. Karttunen R, Karttunen T, Ekre HP, MacDonald TT: Interferon gamma and interleukin 4 secreting cells in the gastric antrum in Helicobacter pylori positive and negative gastritis. Gut 1995, 36:341-345.
16. D'Elios MM, Manghetti M, De Carli M, Costa F, Baldari CT, Burroni D, et al.: T helper 1 effector cells specific for Helicobacter pylori in gastric antrum of patients with peptic ulcer disease. J Immunol 1997, 158:962-967.
17. Bamford KB, Fan X, Crowe SE, Leary JF, Gourley WK, Luthra GK, et al.: Lymphocytes in the human gastric mucosa during Helicobacter pylori have a T helper cell 1 phenotype. Gastroenterology 1998, 114:482-492. This study used immunohistochemistry and flow cytometry of isolated cells to show that the natural T-cell response to H. pylori in humans has a Th1 phenotype.
18. Mohammadi M, Czinn S, Redline R, Nedrud J: Helicobacter specific cell mediated responses display a predominant TH1 phenotype and promote a delayed type hypersensitivity response in the stomachs of mice. J Immunol 1996, 156:4729-4738.
19. Mohammadi M, Nedrud J, Redline R, Lycke N, Czinn SJ: Murine CD4- cell response to helicobacter infection: TH1 cells enhance gastritis and TH2 cells reduce bacterial load. 1997, 113:1848-1857.
20. Saldinger PF, Porta N, Launois P, Louis JA, Waanders GA, Bouzourene H, et al.: Immunization of BALB/c mice with helicobacter urease B induces a T helper 2 response absent in helicobacter infection. 1998, 115:891-897. A progressive switch from a Th1 to a Th2 response has been seen in mice during therapeutic immunization and correlates with clearance of the gastric infection.
21. Blanchard TG, Czinn SJ, Redline RW, Sigmund N, Harriman G, Nedrud JG: Antibody-independent protective mucosal immunity to gastric helicobacter infection in mice. Cell Immunol 1999, 191: 74-80. This study reports the first series of experiments to show that gastric protection is B-cell independent.
22. Kreiss C, Buclin T, Cosma M, Corthesy-Theulaz I, Michetti P: Safety of oral immunization with recombinant urease in patients with Helicobacter pylori infection. Lancet 1996, 347:1630-1631.
23. Michetti P, Kreiss C, Kotloff KL, Porto N, Blanco JL, Bachmann D, et al.: Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 1999, 116:804-812. This is the only report to date of immunization against H. pylori in humans.
24. Hook-Nikanne JP, Aho P, Karkkainon P, Kosunen TU, Salaspuro M: The Helicobacter felis mouse model in assessing anti-helicobacter therapies and gastric mucosal prostaglandin E2 levels, 1996, 31:334-338.
25. Kleanthous H, Myers GA, Georgakopoulos KM, Tibbits TJ, Ingrassia JW, Gray HL, et al.: Rectal and intranasal immunization with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection. Infect Immunol 1998, 66:2879-2886. This study suggests that mucosal routes of immunization may induce higher immune responses than the oral route.
26. Dubois A, Lee CK, Fiala N, Kleanthous H, Mehlman PT, Monath T: Immunization against natural Helicobacter pylori infection in nonhuman primates. Infect Immunol 1998, 66:4340-4346. Prophylaxis is achieved in a natural primate model of H. pylori infection
27. Lee CK, Soike K, Hill J, Georgakopoulos K, Tibbitts T, Ingrassia J, et al.: Immunization with recombinant Helicobacter pylori urease decreases colorization levels following experimental infection of rhesus monkeys. Vaccine 1998, 17:1493-1505. See comment under [26].
28. Ilver D, Arnqvist A, Ogren J, Frick IM, Kersulyte D, Incecik ET, et al.: Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging. Science 1998, 279:373-377. This elegant study demonstrates the relevance of a new binding site for H. pylori.
29. Ferrero RL, Thiberge JM, Kansau I, Wuscher N, Huerre M, Labigne A: The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci U S A 1995, 92:6499-6505.
30. Ghiara P, Rossi M, Marchetti M, Di Tommaso A, Vindigni C, Ciampolini F, et al.: Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection. 1997, 65:4996-5002.
31. Tomb JF, White O, Kerlavage AR, Clayton RA, Sutton GG, Fleischmann RD, et al.: The complete genome sequence of the gastric pathogen Helicobacter pylori. 1997, 388:539-547.
32. Alm RA, Ling LS, Moir DT, King BL, Brown ED, Doig PC, et al.: Ganomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature 1999, 397:176-180. Helicobacter pylori was the first bacterium to be entirely sequenced twice. Complete alignment of the two genomes is reported in this landmark article.
33. Lee A: The Helicobacter pylori genome-new insights into pathogenesis and therapeutics. N Engl J Med 1998, 338:832-833.
34. McAtee C, Lim M, Fung K, Velligan M, Fry K, Chow T, Berg D: Identification of potential diagnostic and vaccine candidates of Helicobacter pylori by two-dimensional gel electrophoresis, sequence analysis, and serum profiling. Clin Diagn Lab Immunol 1998, 5:537-542.
35. Guy B, Hessler C, Fourage S, Haensler J, Vialon-Lafay E, Rokbi B, Millet MJ: Systemic immunization with urease protects mice against Helicobacter pylori infection. Vaccine 1998, 16:850-856. The demonstration that parenteral immunization is possible opens up new avenues for vaccine design. Previous attempts at systemic immunization against H. pylori without adjuvants had failed.
36. Marchetti M, Rossi M, Giannelli V, Giuliani MM, Pizza M, Censini S, et al.: Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. Vaccine 1998, 16:33-37.
37. Lee A, Chen MH: Successful immunization against gastric infection against infection with helicobacter species: use of a cholera toxin B-subunit-whole cell vaccine. Infect Immunol 1994, 62:3594-3597.
38. Blanchard TG, Lycke N, Czinn SJ, Nedrud JG: Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral immunization of mice against Helicobacter felis. Immunology 1998, 94:22-27.
39. Kim SY, Doh HJ, Ahn JS, Ha YJ, Jang MH, Chung SI, Park HJ: Induction of mucosal and systemic immune response by oral immunization with H. pylori lysates encapsulated in poly(D,L-lactide-co-glycolide) microparticles. Vaccine 1999, 17:607-616.
40. Corthésy-Theulaz IE, Hopkins S, Bachmann D, Saldinger PF, Porta N, Haas R, et al.: Mice are protected from Helicobacter pylori infection by nasal immunization with attenuated Salmonella typhimurium phoPc expressing urease A and B subunits. Infect Immunol 1998, 66:581-586. Attenuated recombinant bacteria may represent the best approach to immunization against H. pylori and would be affordable for countries with high prevalences of infection.
41. Gomez-Duarte OG, Lucas B, Yan ZX, Panthel K, Haas R, Meyer TF: Urease subunits A and B delivered by attenuated Salmonella typhimurium vaccine strain protects mice against gastric colonization by Helicobacter pylori. Vaccine 1996, 16:460-471.
42. Kantele A, Westerholm M, Kantele JM, Mäkelä PH, Savilahti E: Homing potentials of circulating antibody-secreting cells after administration of oral or parenteral protein or polysaccharide vaccine in humans. Vaccine 1999, 17:229-236. This paper elegantly demonstrates that lymphocyte homing to the duodenal mucosa is enhanced after oral immunization.
43. Michetti M, Kelly CP, Michetti P: Lymphocytes expressing mucosal homing receptors are required for protection against helicobacter infection in mice. Gastroenterology 1998, 114:A1039.
44. Blanchard TG, Gottwein JM, Targoni OS, Eisenberg JC, Zagorski BM, Trezza RP, et al.: Systemic vaccination inducing either TH1 or TH2 immunity protects mice from challenge with H. pylori. Gastroenterology 1999, 116:A695.
45. Guy B, Hessler C, Fourage S, Rokbi B, Quentin Millet M: Comparison between targeted and untargeted systemic immunization with adjuvanted urease to cure Helicobacter pylori infection in mice. Vaccine 1999, 17:1130-1135.